Printer Friendly

Progressive Multifocal Leukoencephalopathy Treatment Market to Register High Revenue Growth at 2.8%.

[ClickPress, Wed Oct 10 2018] Progressive multifocal leukoencephalopathy (PML) is a rare, fatal disease that causes continual damage to the white matter of the brain, at different locations. Caused by JC Virus, PML is mostly reported in cancer patients on chronic immunosuppressive medications or those suffering from AIDS. Also, patients with transplants, multiple sclerosis or other variants of autoimmune diseases are susceptible to progressive multifocal leukoencephalopathy. With no specific treatment, anti-HIV drugs are being increasingly used for controlling progressive multifocal leukoencephalopathy. Considering the rarity of the disease, with no specific treatment options available, the global progressive multifocal leukoencephalopathy treatment market is expected to remain in the low growth-low volume quadrant over the forecast period of 2018-2026, representing a sluggish 2.8% CAGR, predicts Persistence Market Research. The global progressive multifocal leukoencephalopathy treatment market is likely to reach a valuation of US$ 150.5 Mn by 2026 by the end of 2026. While the North America progressive multifocal leukoencephalopathy treatment market is anticipated to be the most lucrative, PML market in Asia Pacific is expected to record comparatively faster growth considering increasing prevalence of HIV infection and awareness.

Copyright [c] 2018 ClickPress Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2018 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ClickPress
Date:Oct 10, 2018
Words:198
Previous Article:Piling Sheet, Anchoring Equipment, and Trench Shoring System Market to Witness Steady Growth at 5.5%.
Next Article:Vertical Lift Module Market Pegged to Surpass US$ 1.5 Bn Valuation by End of 2018-2026.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters